This year’s BIO-CEO conference included a well-attended RNAi panel discussion, featuring the heads of several RNAi therapeutics firms, entitled: “What’s All the Fuss about RNAi?” Although it remains uncertain whether the participants’ presentations — which, for the most part, amounted to corporate overviews well-suited to an audience unfamiliar with RNAi — helped answer this question, they did provide a few new details about each company’s ongoing activities.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.